Back to Search
Start Over
DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy.
- Source :
-
International journal of cancer [Int J Cancer] 2000 Mar 20; Vol. 89 (2), pp. 160-6. - Publication Year :
- 2000
-
Abstract
- We aimed to investigate whether biological factors related to radiosensitivity and chemosensitivity have prognostic significance in non-small-cell-lung-cancer (NSCLC) patients treated with daily low doses of cisplatin and radiotherapy. We treated 27 NSCLC patients with concomitant daily low-dose cisplatin and radiotherapy between 1993 and 1995. Tumour specimens were analyzed for p53 and bcl-2 expression, and for cell proliferation using antibodies against ki-67. In addition, apoptosis was measured by an end-labeling technique (TUNEL). Finally, cisplatin-induced DNA modification in buccal cells was assessed immunocytochemically using a specific anti-serum. Univariate and multivariate analyses were performed to assess the association between the different variables and survival. The median follow-up was 41 months, and 21 patients (78%) have died. In a univariate analysis, age, tumour stage and cisplatin-DNA-adduct staining were the only factors significantly associated with survival (p < 0.05, log-rank test). p53, bcl-2, Ki-67 and apoptosis showed no relationship with outcome. Multivariate analysis revealed that cisplatin-DNA-adduct staining remained an independent prognostic factor (hazard ratio, 0.10, 95% CI, 0.02-0.49), with shorter survival times for patients with low adduct staining.<br /> (Copyright 2000 Wiley-Liss, Inc.)
- Subjects :
- Adult
Aged
Analysis of Variance
Apoptosis
Carcinoma, Non-Small-Cell Lung chemistry
Carcinoma, Non-Small-Cell Lung drug therapy
Carcinoma, Non-Small-Cell Lung radiotherapy
Combined Modality Therapy
Female
Humans
Immunohistochemistry
Ki-67 Antigen analysis
Lung Neoplasms chemistry
Lung Neoplasms drug therapy
Lung Neoplasms radiotherapy
Male
Middle Aged
Predictive Value of Tests
Prognosis
Proportional Hazards Models
Proto-Oncogene Proteins c-bcl-2 analysis
Radiation-Sensitizing Agents therapeutic use
Radiotherapy Dosage
Tumor Suppressor Protein p53 analysis
Antineoplastic Agents therapeutic use
Carcinoma, Non-Small-Cell Lung genetics
Carcinoma, Non-Small-Cell Lung therapy
Cisplatin therapeutic use
DNA Adducts analysis
DNA, Neoplasm analysis
Lung Neoplasms genetics
Lung Neoplasms therapy
Subjects
Details
- Language :
- English
- ISSN :
- 0020-7136
- Volume :
- 89
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- International journal of cancer
- Publication Type :
- Academic Journal
- Accession number :
- 10754494